Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Established in 1988, Antisoma is a biopharmaceutical company specialising in the preclinical and clinical development
of products for the treatment of cancer. According to the company, its expertise is cost-effective product development,
generating maximum risk reduction per unit invested by focusing on development up to Phase III studies.
Antisoma's corporate strategy is to fill its development pipeline by acquiring promising early-stage cancer products from
both academic and commercial institutions rather than from in-house research. Antisoma has in-licensed much of its
current intellectual property, including clinical development candidates AS1404 (DMXAA) and Therex. The company's
core activity is the management of preclinical and clinical development to demonstrate the safety and efficacy of drug
candidates. Antisoma optimises drug design and compiles a package of data to support regulatory submissions for
clinical studies and ultimately sale of the product. Generally, pharmaceutical partners will complete clinical
development, filing for regulatory approval and marketing.